ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026
Formononetin attenuates glucocorticoid-induced osteoporosis via multiple osteoimmunological pathways: evidence from zebrafish and network pharmacology.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Osteoporosis is a prevalent metabolic bone disease that requires multi-target therapeutic strategies. Formononetin (FMN), a bioactive isoflavone derived from Astragalus species, has shown potential in promoting bone health; however, its systemic mechanisms remain poorly understood. In this study, we evaluated the anti-osteoporotic effects of FMN using a glucocorticoid-induced bone loss model in zebrafish. Our results demonstrate that FMN significantly and dose-dependently promotes bone mineralization and effectively reverses glucocorticoid-induced skeletal damage. By integrating network pharmacology and molecular docking with experimental validation, we identified a multi-target mechanism underlying FMN's protective effects. FMN was found to regulate several key signaling pathways, including the PI3K-AKT and estrogen pathways, and its therapeutic impact was confirmed by the rectified expression of core genes involved in bone homeostasis and inflammation. This study reveals that FMN exerts its anti-osteoporotic effects through the coordinated regulation of growth factor signaling, calcium homeostasis, and the oxidative stress-bone metabolism axis. Our findings provide a systematic theoretical foundation for developing FMN as a promising natural therapeutic agent for osteoporosis through the modulation of osteoimmunology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.